Brief: Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion With FDA
29/05/2026 13:14
BRIEF-Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion With FDA May 29 (Reuters) - Replimune Group Inc REPL.O:
ANNOUNCES PLANNED RP1 BLA RESUBMISSION FOLLOWING PRODUCTIVE DISCUSSION WITH FDA
TO RESUBMIT RP1 BLA; FDA TO PRIORITIZE REVIEW AS URGENT
TO RESUBMIT RP1 BLA FOR ADVANCED MELANOMA AFTER ALIGNMENT WITH FDA
Source text: ID:nGNX7Bsnfr
Further company coverage: REPL.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly